Raymond James Financial Services Advisors, Inc. Recursion Pharmaceuticals, Inc. Transaction History
Raymond James Financial Services Advisors, Inc.
- $73.5 Billion
- Q3 2024
A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 67,401 shares of RXRX stock, worth $494,049. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,401
Previous 89,980
25.09%
Holding current value
$494,049
Previous $674,000
34.12%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RXRX
# of Institutions
291Shares Held
242MCall Options Held
1.35MPut Options Held
2.32M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.8MShares$240 Million2.05% of portfolio
-
Baillie Gifford & CO25.2MShares$185 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA24.3MShares$178 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$127 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA15.4MShares$113 Million1.41% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.32B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...